168 related articles for article (PubMed ID: 20686235)
21. UGT2B7*3 did not affect the pharmacokinetics of R- and S-carvedilol in healthy Japanese.
Honda M; Toyoda W; Shimizu T; Horiuchi I; Kayano Y; Taguchi M; Nozawa T; Inoue H; Hashimoto Y
Drug Metab Pharmacokinet; 2007 Oct; 22(5):382-6. PubMed ID: 17965522
[TBL] [Abstract][Full Text] [Related]
22. Measurement of carvedilol enantiomers in human plasma and urine using S-naproxen chloride for chiral derivatization.
Spahn H; Henke W; Langguth P; Schloos J; Mutschler E
Arch Pharm (Weinheim); 1990 Aug; 323(8):465-9. PubMed ID: 1980583
[TBL] [Abstract][Full Text] [Related]
23. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D
Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229
[TBL] [Abstract][Full Text] [Related]
24. Exercise does not affect plasma concentrations of (R)- and (S)-carvedilol.
Stoschitzky K; Koshucharova G; Zweiker R; Lercher P; Maier R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W
Cardiovasc Drugs Ther; 2002 Mar; 16(2):133-40. PubMed ID: 12090906
[TBL] [Abstract][Full Text] [Related]
25. Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues.
Stahl E; Mutschler E; Baumgartner U; Spahn-Langguth H
Arch Pharm (Weinheim); 1993 Sep; 326(9):529-33. PubMed ID: 7902078
[TBL] [Abstract][Full Text] [Related]
26. Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure.
Refsgaard J; Thomsen C; Andreasen F; Gøtzsche O
Eur J Heart Fail; 2002 Aug; 4(4):445-53. PubMed ID: 12167382
[TBL] [Abstract][Full Text] [Related]
27. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
Kim MS; Baek IH
Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006
[TBL] [Abstract][Full Text] [Related]
28. Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study.
Nardotto GHB; Coelho EB; Marques MP; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():173-180. PubMed ID: 26927877
[TBL] [Abstract][Full Text] [Related]
29. Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol.
Fukumoto K; Kobayashi T; Komamura K; Kamakura S; Kitakaze M; Ueno K
Drug Metab Pharmacokinet; 2005 Dec; 20(6):423-7. PubMed ID: 16415527
[TBL] [Abstract][Full Text] [Related]
30. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
31. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo.
Kindermann M; Maack C; Schaller S; Finkler N; Schmidt KI; Läer S; Wuttke H; Schäfers HJ; Böhm M
Circulation; 2004 Jun; 109(25):3182-90. PubMed ID: 15184276
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
Nardotto GHB; Lanchote VL; Coelho EB; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S108-S115. PubMed ID: 28522373
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.
Albers S; Meibohm B; Mir TS; Läer S
Br J Clin Pharmacol; 2008 Apr; 65(4):511-22. PubMed ID: 17995971
[TBL] [Abstract][Full Text] [Related]
34. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate.
Othman AA; Tenero DM; Boyle DA; Eddington ND; Fossler MJ
AAPS J; 2007 Jun; 9(2):E208-18. PubMed ID: 17614362
[TBL] [Abstract][Full Text] [Related]
36. Population Pharmacokinetic-Pharmacodynamic Modeling of Carvedilol to Evaluate the Effect of Cytochrome P450 2D6 Genotype on the Heart Rate Reduction.
Hwang S; Lee S; Yoon J; Chung JY
J Korean Med Sci; 2023 Jun; 38(22):e173. PubMed ID: 37272562
[TBL] [Abstract][Full Text] [Related]
37. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure.
Macdonald PS; Keogh AM; Aboyoun CL; Lund M; Amor R; McCaffrey DJ
J Am Coll Cardiol; 1999 Mar; 33(4):924-31. PubMed ID: 10091817
[TBL] [Abstract][Full Text] [Related]
38. Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol.
Kubo T; Azevedo ER; Newton GE; Parker JD; Floras JS
J Am Coll Cardiol; 2001 Nov; 38(5):1463-9. PubMed ID: 11691524
[TBL] [Abstract][Full Text] [Related]
39. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound.
Neugebauer G; Akpan W; Kaufmann B; Reiff K
Eur J Clin Pharmacol; 1990; 38 Suppl 2():S108-11. PubMed ID: 1974498
[TBL] [Abstract][Full Text] [Related]
40. Value of carvedilol in congestive heart failure secondary to coronary artery disease.
Das Gupta P; Broadhurst P; Raftery EB; Lahiri A
Am J Cardiol; 1990 Nov; 66(15):1118-23. PubMed ID: 1977300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
